Treatment Changes
Cross-source consensus on Treatment Changes from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Risks & contraindications
Evidence quality
Highlighted claims
- The median time until the next treatment change shortened with each successive change, from 207 days before the first change to 165 days before the fourth. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
- Overall, 53% of patients experienced at least one treatment change during the 24-month study. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
- Step-up or switch was the most common first treatment change, occurring in 38% of patients. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
- Intolerance was the strongest predictor of any treatment change, with a hazard ratio of 4.43, followed by lack of efficacy with a hazard ratio of 3.30. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
- Disease activity measured by DAS28-4 using erythrocyte sedimentation rate was not significantly correlated with treatment changes. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)